Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12763742 | 0.78 | HCAR2 (0.43) | KMT2ALMNAMAPTHTTSMN1; SMN2 | |
| SCHEMBL17148520 | 0.75 | KMT2A (0.39) | KMT2AMEN1LMNAMAPTHTT | |
| SCHEMBL17148533 | 0.73 | HTT (0.41) | KMT2ALMNAMAPTHTTSMN1; SMN2 | |
| SCHEMBL2609312 | 0.69 | LMNA (0.44) | KMT2AMEN1LMNAMAPTHTT | |
| SCHEMBL14132578 | 0.67 | HTT (0.47) | KMT2AMEN1LMNAHTTSMN1; SMN2 | |
| SCHEMBL12248259 | 0.67 | CCR1 (0.35) | KMT2ALMNASMN1; SMN2 | |
| SCHEMBL15599174 | 0.67 | KMT2A (0.34) | KMT2AMEN1LMNASMN1; SMN2 | |
| SCHEMBL21139639 | 0.66 | KMT2A (0.36) | KMT2AMEN1LMNASMN1; SMN2 | |
| SCHEMBL16139588 | 0.66 | S1PR1 (0.42) | KMT2AMEN1LMNAMAPTHTT | |
| SCHEMBL12186135 | 0.66 | THRB (0.38) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8754226-B2 | Piperidinyl-substituted lactams as GPR119 modulators | ARRAY BIOPHARMA INC. (US) | 2014-06-17 | — | — | US | disclosed |
| US-20130158009-A1 | PIPERIDINYL-SUBSTITUTED LACTAMS AS GPR119 MODULATORS | ARRAY BIOPHARMA, INC. | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158009-A1 | PIPERIDINYL-SUBSTITUTED LACTAMS AS GPR119 MODULATORS | GPR119, GPR139, GPR39 | KMT2A 1376/4885MEN1 3405/4885LMNA 2220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.